Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Vantage 1.5T MR System Receives FDA Clearance for AI-Based Image Reconstruction Technology Announces Canon Medical Systems USA

Canon Medical Systems USA, Inc. has received 510(k) clearance on its Advanced intelligent Clear-IQ Engine (AiCE)* for the Vantage Orian 1.5T MR system, continuing to expand access to its new Deep Learning Reconstruction (DLR) technology.

This technology, which is also available on the Vantage Galan 3T MR system and across a majority of Canon Medical’s CT product portfolio, uses a deep learning algorithm to differentiate true signal from noise so that it can suppress noise while enhancing signal, forging a new frontier for image reconstruction.

“The Vantage Orian was designed to increase productivity while ensuring patient comfort and delivering uncompromised clinical confidence,” said Jonathan Furuyama, managing director, MR Business Unit, Canon Medical Systems USA, Inc. “Now with the addition of AiCE, we’re elevating MR imaging capabilities for our customers by bringing the power of AI to routine imaging, allowing them to use techniques that weren’t clinically practical before.”

To showcase how AiCE can help clinicians obtain higher signal-to-noise ratio**, Canon Medical has launched an image challenge where visitors can compare images taken on the Vantage Orian 1.5T system using AiCE with standard 3T MRI images. To take the challenge and compare the image quality, click here.

Aice Mr Orian

AiCE was trained using vast amounts of high-quality image data, and features a deep learning neural network that can reduce noise and boost signal to quickly deliver sharp, clear and distinct images, further opening doors for advancements in MR imaging. Capabilities include:

  • High-quality images: AiCE allows for the differentiation of true signal from noise through deep learning innovation to match the spatial resolution and low-noise properties of advanced scanning and reconstruction while maintaining the true structure of the anatomy. Using AiCE may help clinicians expand clinical capabilities beyond traditional 1.5T MR.
  • Seamless integration into routine practice: AiCE is the world’s first fully integrated deep learning reconstruction for MR, and is built directly into the scan protocols for seamless workflow.
  • Preferred AiCE MR image quality over non-AI reconstruction images: Following a blinded image comparison of AiCE DLR reconstructed images with images reconstructed with conventional methods without AiCE, physicians stated preference for AiCE images for clarity and resolution.
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy